NRIX: Bull Flag detected on 26 Aug 2026

NRIX has formed a bull flag pattern amid its registrational program advancement for bexobrutideg. The stock trades at $26.95, consolidating between resistance at $25.08 and support at $21.23—a tight range after a 55% gain over three months. Pattern quality scores 76.1 overall, with solid structure (14.4/15) and breakout strength (11.3/13), though volume trails slightly below average at 0.94x. The 70.98% win probability suggests this consolidation has meaningful directional conviction. Technical positioning is neutral with RSI at 63.45 (not overbought) and a negative MACD histogram (-0.0771) flagging weakening momentum despite the 3-month advance.

In June 2026, Nurix entered a transformative global collaboration with Roche for bexobrutideg with potential total payments of up to $2.3 billion, including a $700 million upfront payment. Q2 2026 revenue was $9.0 million with net loss of $89.5 million and pro-forma cash of about $1.14 billion including the expected Roche upfront. On August 4, 2026, Nurix earned a $10 million milestone payment following Sanofi's initiation of a Phase 1 trial of SAR448272/NX-3911. The company presented preclinical data at the 2026 AACR meeting highlighting progress across multiple protein degradation programs. Sector tailwinds remain bullish (regime score 0.87), though broader market shows bearish tone (regime score -0.22). The stock's 55% quarterly surge reflects market enthusiasm for the Roche partnership and advancing clinical catalysts.

A successful bull flag breakout above $25.08 resistance would target $27.84 conservatively—approximately 3.5% upside from current levels. Historical bull flags in this quality range (76.1 score) show 70.98% breakout success probability. Volume confirmation matters: current volume (1.02M shares) tracks near 20-day average, so we'd expect above-average institutional accumulation during breakout. Invalidation occurs at key support $21.23, representing approximately 21% downside risk. The pattern structure—tight consolidation after a significant advance—is textbook for continuation; sustained above $25.08 with volume expansion would confirm bullish intent toward the measured move target.

Despite the $1.14 billion pro-forma cash position, net losses remain substantial at $89.5 million in Q2, and pre-revenue clinical-stage biotech carries binary event risk around trial outcomes. The Phase 3 DAYBreak CLL-306 trial targeting midyear 2026 initiation represents a key inflection point—adverse efficacy/safety readouts would crater the setup. Roche partnership dependency creates counterparty risk; any strategic shift by the pharma giant could pressure valuations. Beta of 0.9 suggests moderate volatility, but biotech volatility spikes on clinical news. The negative MACD histogram signals waning momentum despite price strength—this divergence may precede consolidation breakdown. With broader market in bearish regime (-0.22), institutional rotation pressure could overcome sector tailwinds if growth stocks face renewed selling.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.